Research
Hormonal
GLP-1 receptor agonists (semaglutide) and dual incretin agonists (tirzepatide) achieve 15-20% total body weight loss, rivaling the efficacy of bariatric surgery.
If you have obesity, these medications offer a powerful, non-surgical path to significant weight loss (15-20%). They require a weekly injection and likely lifelong use, but they can improve metabolic health and may be more accessible than surgery for some. Discuss with your doctor if you are a candidate.
GoodSupportsHIGH confidence
Clinical trials consistently show that these medications can lower body weight by 15-20%, a remarkable shift that challenges formerly held assumptions about the limitations of non-surgical weight loss.
Why this rating
Based on landmark clinical trials (STEP, SURMOUNT-1) cited in a narrative review.
Source
The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment
Mena Louis et al. · Cureus · 2025
DOI 10.7759/cureus.83903
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery remains the most effective long-term treatment for severe obesity, offering superior durability and comorbidity remission compared to pharmacotherapy.Strong
- Pharmacotherapy may reduce bariatric surgical volume, particularly among patients with BMI 30-40, by providing a less invasive alternative.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →